Spyre Therapeutics Stock Buy Hold or Sell Recommendation
| SYRE Stock | 27.70 0.70 2.59% |
Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding Spyre Therapeutics is 'Hold'. Macroaxis provides Spyre Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding SYRE positions.
Check out Spyre Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide. Note, we conduct extensive research on individual companies such as Spyre and provide practical buy, sell, or hold advice based on investors' constraints. Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Spyre |
Execute Spyre Therapeutics Buy or Sell Advice
The Spyre recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Spyre Therapeutics. Macroaxis does not own or have any residual interests in Spyre Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Spyre Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Spyre Therapeutics Trading Alerts and Improvement Suggestions
| Spyre Therapeutics had very high historical volatility over the last 90 days | |
| Spyre Therapeutics was previously known as Aeglea Bio Therapeutics and was traded on NASDAQ Exchange under the symbol AGLE. | |
| The company reported the previous year's revenue of 886 K. Net Loss for the year was (338.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Spyre Therapeutics generates negative cash flow from operations | |
| Spyre Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Fairmount Funds Management LLCs Strategic Acquisition in Oruka Therapeutics Inc |
Spyre Therapeutics Returns Distribution Density
The distribution of Spyre Therapeutics' historical returns is an attempt to chart the uncertainty of Spyre Therapeutics' future price movements. The chart of the probability distribution of Spyre Therapeutics daily returns describes the distribution of returns around its average expected value. We use Spyre Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Spyre Therapeutics returns is essential to provide solid investment advice for Spyre Therapeutics.
| Mean Return | 0.24 | Value At Risk | -6.63 | Potential Upside | 5.30 | Standard Deviation | 3.73 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Spyre Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Spyre Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (3.2M) | 71.2M | (75.0M) | 19.4M | 152.8M | 160.4M | |
| Free Cash Flow | (67.2M) | (80.1M) | (54.3M) | (80.2M) | (99.9M) | (94.9M) | |
| Depreciation | 901K | 996K | 1.6M | 1.6M | 744K | 888.0K | |
| Other Non Cash Items | 3.8M | 619K | 90K | 823K | 217.7M | 228.6M | |
| Capital Expenditures | 422K | 1.5M | 4.3M | 573K | 38K | 0.0 | |
| Net Income | (78.3M) | (80.9M) | (65.8M) | (83.8M) | (338.8M) | (321.9M) | |
| End Period Cash Flow | 19.3M | 91.9M | 17.0M | 36.4M | 189.2M | 198.7M |
Spyre Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Spyre Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Spyre Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Spyre stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.06 | |
β | Beta against Dow Jones | 2.37 | |
σ | Overall volatility | 3.68 | |
Ir | Information ratio | 0.03 |
Spyre Therapeutics Volatility Alert
Spyre Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Spyre Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Spyre Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Spyre Therapeutics Fundamentals Vs Peers
Comparing Spyre Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Spyre Therapeutics' direct or indirect competition across all of the common fundamentals between Spyre Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Spyre Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Spyre Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Spyre Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Spyre Therapeutics to competition |
| Fundamentals | Spyre Therapeutics | Peer Average |
| Return On Equity | -0.92 | -0.31 |
| Return On Asset | -0.39 | -0.14 |
| Current Valuation | 1.47 B | 16.62 B |
| Shares Outstanding | 58.71 M | 571.82 M |
| Shares Owned By Insiders | 8.80 % | 10.09 % |
| Shares Owned By Institutions | 88.30 % | 39.21 % |
| Number Of Shares Shorted | 8.25 M | 4.71 M |
| Price To Book | 9.48 X | 9.51 X |
| Price To Sales | 2,210 X | 11.42 X |
| Revenue | 886 K | 9.43 B |
| EBITDA | (242.3 M) | 3.9 B |
| Net Income | (338.79 M) | 570.98 M |
| Total Debt | 84.56 M | 5.32 B |
| Book Value Per Share | 3.34 X | 1.93 K |
| Cash Flow From Operations | (99.91 M) | 971.22 M |
| Short Ratio | 21.97 X | 4.00 X |
| Earnings Per Share | (37.90) X | 3.12 X |
| Target Price | 58.63 | |
| Number Of Employees | 30 | 18.84 K |
| Beta | 2.91 | -0.15 |
| Market Capitalization | 1.63 B | 19.03 B |
| Total Asset | 341.86 M | 29.47 B |
| Retained Earnings | (764.41 M) | 9.33 B |
| Working Capital | 309.55 M | 1.48 B |
| Net Asset | 341.86 M |
Note: Disposition of 6700 shares by Albers Jeffrey W. of Spyre Therapeutics at 36.7631 subject to Rule 16b-3 [view details]
Spyre Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Spyre . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Spyre Therapeutics Buy or Sell Advice
When is the right time to buy or sell Spyre Therapeutics? Buying financial instruments such as Spyre Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Spyre Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Iron Thematic Idea Now
Iron
Companies involved in production of steel and iron. The Iron theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Iron Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Spyre Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (37.90) | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.